MPM Oncology Impact Management »

Aclaris Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Aclaris Therapeutics (ACRS) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Aclaris Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aclaris Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aclaris Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $1.5M 392k 3.75

More positions owned by MPM Oncology Impact Management

DBV Technologies S A Sponsored Ads (DBVT)
Cullinan Therapeutics Common (CGEM)
Aktis Oncology Common
Liquidia Corporation Common (LQDA)
Alumis Common (ALMS)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Corcept Therapeutics Common (CORT)
Trevi Therapeutics Common (TRVI)
Dianthus Therapeutics Common (DNTH)
Xenon Pharmaceuticals Common (XENE)
MoonLake Immunotherapeutics Class A Ord (MLTX)
Travere Therapeutics Common (TVTX)
Evommune Common (EVMN)

View all positions for MPM Oncology Impact Management

Top funds holding Aclaris Therapeutics

BML Capital Management
Deep Track Capital
BlackRock
RA Capital Management
Vivo Capital
Vanguard Group
Vanguard Capital Management
Frazier Life Sciences Management
Rock Springs Capital Management
Decheng Capital
Adage Capital Partners GP
Balyasny Asset Management
Citadel Advisors
Morgan Stanley
Geode Capital Management

View all funds holding Aclaris Therapeutics